Identification

Name
Fluvastatin
Accession Number
DB01095  (APRD00346)
Type
Small Molecule
Groups
Approved
Description

Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. It is also the first entirely synthetic HMG-CoA reductase inhibitor and is structurally distinct from the fungal derivatives of this therapeutic class. Fluvastatin is a racemate comprising equimolar amounts of (3R,5S)- and (3S,5R)-fluvastatin.

Structure
Thumb
Synonyms
  • fluvastatina
  • fluvastatine
  • fluvastatinum
Product Ingredients
IngredientUNIICASInChI Key
Fluvastatin sodiumPYF7O1FV7F93957-55-2ZGGHKIMDNBDHJB-NRFPMOEYSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LescolCapsule40 mg/1OralPhysicians Total Care, Inc.2002-03-08Not applicableUs
LescolCapsule20 mg/1OralNovartis1993-12-302017-07-10Us00078 0176 15 nlmimage10 b80edc36
LescolCapsule20 mg/1OralPhysicians Total Care, Inc.1994-06-10Not applicableUs
LescolCapsule40 mg/1OralNovartis1993-12-302017-07-10Us
Lescol 20mgCapsule20 mgOralNovartis1994-12-31Not applicableCanada
Lescol 40mgCapsule40 mgOralNovartis1994-12-31Not applicableCanada
Lescol XLTablet, extended release80 mg/1OralNovartis2000-10-06Not applicableUs00078 0354 05 nlmimage10 37091bf8
Lescol XLTablet, extended release80 mgOralNovartis2004-04-05Not applicableCanada
Lescol XLTablet, extended release80 mg/1OralCarilion Materials Management2000-10-06Not applicableUs
Lescol XLTablet, extended release80 mg/1OralPhysicians Total Care, Inc.2002-03-12Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FluvastatinCapsule20 mg/1OralTeva2012-07-05Not applicableUs00093 7442 56 nlmimage10 30271848
FluvastatinCapsule40 mg/1OralTeva2012-07-05Not applicableUs00093 7443 56 nlmimage10 052702b8
Fluvastatin SodiumCapsule20 mg/1OralMylan Pharmaceuticals2013-03-19Not applicableUs
Fluvastatin SodiumCapsule40 mg/1OralCarilion Materials Management2013-03-19Not applicableUs
Fluvastatin SodiumTablet, film coated, extended release80 mg/1OralTeva2016-06-02Not applicableUs
Fluvastatin SodiumTablet, film coated, extended release80 mg/1OralMylan Pharmaceuticals2015-09-11Not applicableUs
Fluvastatin SodiumCapsule40 mg/1OralMylan Pharmaceuticals2013-03-19Not applicableUs00378 8021 93 nlmimage10 043b0218
Fluvastatin SodiumCapsule20 mg/1OralCarilion Materials Management2013-03-19Not applicableUs00378 8020 77 nlmimage10 043b0248
Fluvastatin Sodium ERTablet, extended release80 mg/1OralSandoz2015-10-16Not applicableUs
Teva-fluvastatinCapsule40 mgOralTeva2012-12-11Not applicableCanada
International/Other Brands
Canef (AstraZeneca) / Cranoc (Astellas)
Categories
UNII
4L066368AS
CAS number
93957-54-1
Weight
Average: 411.4659
Monoisotopic: 411.18458653
Chemical Formula
C24H26FNO4
InChI Key
FJLGEFLZQAZZCD-JUFISIKESA-N
InChI
InChI=1S/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)/b12-11+/t18-,19-/m0/s1
IUPAC Name
(3S,5R,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
SMILES
CC(C)N1C(\C=C\[[email protected]](O)C[[email protected]](O)CC(O)=O)=C(C2=CC=C(F)C=C2)C2=CC=CC=C12

Pharmacology

Indication

To be used as an adjunct to dietary therapy to prevent cardiovascular events. May be used as secondary prevention in patients with coronary heart disease (CHD) to reduce the risk of requiring coronary revascularization procedures, for reducing progression of coronary atherosclerosis in hypercholesterolemic patients with CHD, and for the treatment of primary hypercholesterolemia and mixed dyslidipidemia.

Structured Indications
Pharmacodynamics

Fluvastatin, the first synthetically-derived HMG-CoA reductase inhibitor, is a hydrophilic, acidic, antilipemic agent used to lower cholesterol and triglyceride levels associated with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson types IIa and IIb), to slow the progression of coronary atherosclerosis in patients with CHD and as secondary prevention therapy in patients with CHD to reduce the risk of requiring coronary revascularization procedures. Although similar to lovastatin, simvastatin, and pravastatin, fluvastatin has a shorter half-life, no active metabolites, extensive protein binding, and minimal CSF penetration. Fluvastatin acts primarily in the liver. It is prepared as a racemate of two erythro enantiomers of which the 3R,5S enantiomer exerts the pharmacologic effect.

Mechanism of action

Fluvastatin selectively and competitively inhibits the hepatic enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase is responsible for converting HMG-CoA to mevalonate, the rate-limiting step in cholesterol biosynthesis. Inhibition results in a decrease in hepatic cholesterol levels which stimulates the synthesis of LDL receptors and increases hepatic uptake of LDL cholesterol. The end result is decreased levels of plasma total and LDL cholesterol.

TargetActionsOrganism
A3-hydroxy-3-methylglutaryl-coenzyme A reductase
inhibitor
Human
Absorption

Rapidly and almost completely absorbed (> 90%), but undergoes extensive first pass metabolism. Bioavailability is 24% (range 9-50%) when a 10 mg dose is given. The mean relative bioavailability of the extended-release tablet is 29% (range: 9% to 66%) compared to an immediate-release capsule administered under fasting conditions. When given orally, fluvastatin reaches peak concentrations (Tmax) in less than one hour. Taking the extended release tablet with a high-fat meal will delay absorption (Tmax = 6 hours) and increase bioavailability by approximately 50%. However, the maximum concentration of fluvastatin sodium extended-release tablets seen after a high fat meal is less than the peak concentration following a single dose or twice daily dose of the 40 mg fluvastatin capsule.

Volume of distribution
  • 0.35 L/kg
Protein binding

98% bound to plasma proteins. At therapeutic concentrations, the protein binding of fluvastatin is not affected by warfarin, salicylic acid and glyburide.

Metabolism

Undergoes hepatic metabolism primarily via hydroxylation of the indole ring at the 5- and 6-positions to 5-hydroxy fluvastatin and 6-hydroxy fluvastatin, respectively. N-dealkylation to N-desisopropyl fluvastatin and beta-oxidation of the side chain also occurs. Metabolized primarily by the CYP2C9 isozyme system (75%), and to a lesser extent by CYP3A4 (~20%) and CYP2C8 (~5%). Hydroxylated metabolites retain some pharmcological activity, but are present as conjugates (glucuronides and sulfates) in the blood and are rapidly eliminated via bile into feces. Both enantiomers of fluvastatin are metabolized in a similar manner. Fluvastatin also undergoes glucuronidation via UGT enzymes.

Route of elimination

When orally administered, fluvastatin is primarily excreted in the faces ( ~90%) as metabolites, with less than 2% present as unchanged drug. Approximately 5% was recovered in the urine.

Half life

3 hours

Clearance
  • 0.8 L/h/kg
  • 107 ± 38.1 L/h [Hypercholesterolemia patients receiving a single dose of 20 mg]
  • 87.8 ± 45 L/h [Hypercholesterolemia patients receiving 20 mg twice daily]
  • 108 ± 44.7 L/h [Hypercholesterolemia patients receiving 40 mg single]
  • 64.2 ± 21.1 L/h [Hypercholesterolemia patients receiving 40 mg twice daily]
Toxicity

Generally well-tolerated. May cause gastrointestinal upset (diarrhea, nausea, constipation, gas, abdominal pain), myotoxicity (mypothy, myositis, rhabdomyolysis), and hepatotoxicity.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Fluvastatin Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
6-Deoxyerythronolide BThe risk or severity of rhabdomyolysis can be increased when 6-Deoxyerythronolide B is combined with Fluvastatin.Experimental
AbirateroneThe serum concentration of Fluvastatin can be increased when it is combined with Abiraterone.Approved
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Fluvastatin.Approved, Investigational
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Fluvastatin.Approved, Investigational
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Fluvastatin.Approved
AcetazolamideThe serum concentration of Fluvastatin can be increased when it is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Fluvastatin.Approved, Vet Approved
AcipimoxAcipimox may increase the myopathic rhabdomyolysis activities of Fluvastatin.Approved, Investigational
AldesleukinThe serum concentration of Fluvastatin can be increased when it is combined with Aldesleukin.Approved
AlmasilateThe serum concentration of Fluvastatin can be decreased when it is combined with Almasilate.Approved, Experimental
AloglutamolThe serum concentration of Fluvastatin can be decreased when it is combined with Aloglutamol.Experimental
AlosetronThe metabolism of Alosetron can be decreased when combined with Fluvastatin.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Fluvastatin.Approved, Illicit, Investigational
AluminiumThe serum concentration of Fluvastatin can be decreased when it is combined with Aluminium.Approved, Investigational
Aluminium acetoacetateThe serum concentration of Fluvastatin can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Fluvastatin can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe serum concentration of Fluvastatin can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
AmbroxolThe serum concentration of Fluvastatin can be increased when it is combined with Ambroxol.Approved, Investigational
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Fluvastatin.Approved, Withdrawn
AmiodaroneThe serum concentration of Fluvastatin can be decreased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Fluvastatin.Approved
AmlodipineThe serum concentration of Fluvastatin can be increased when it is combined with Amlodipine.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Fluvastatin.Approved, Investigational
Amphotericin BThe risk or severity of rhabdomyolysis can be increased when Amphotericin B is combined with Fluvastatin.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Fluvastatin.Approved, Investigational
AnastrozoleThe serum concentration of Fluvastatin can be increased when it is combined with Anastrozole.Approved, Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Fluvastatin.Approved, Investigational
ApalutamideThe serum concentration of Fluvastatin can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe metabolism of Apixaban can be decreased when combined with Fluvastatin.Approved
AprepitantThe serum concentration of Fluvastatin can be increased when it is combined with Aprepitant.Approved, Investigational
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Fluvastatin.Experimental
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Fluvastatin.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Fluvastatin.Approved, Investigational
Arsenic trioxideThe serum concentration of Fluvastatin can be increased when it is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe metabolism of Fluvastatin can be decreased when combined with Artemether.Approved
AstemizoleThe serum concentration of Fluvastatin can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe risk or severity of rhabdomyolysis can be increased when Atazanavir is combined with Fluvastatin.Approved, Investigational
AtomoxetineThe metabolism of Fluvastatin can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Fluvastatin is combined with Atorvastatin.Approved
AVE9633The risk or severity of rhabdomyolysis can be increased when AVE9633 is combined with Fluvastatin.Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Fluvastatin.Approved
AzithromycinThe risk or severity of rhabdomyolysis can be increased when Azithromycin is combined with Fluvastatin.Approved
BetamethasoneThe serum concentration of Fluvastatin can be increased when it is combined with Betamethasone.Approved, Vet Approved
BetaxololThe metabolism of Fluvastatin can be decreased when combined with Betaxolol.Approved, Investigational
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Fluvastatin.Approved, Investigational
BezafibrateBezafibrate may increase the myopathic rhabdomyolysis activities of Fluvastatin.Approved, Investigational
BicalutamideThe serum concentration of Fluvastatin can be increased when it is combined with Bicalutamide.Approved
BifonazoleThe serum concentration of Fluvastatin can be increased when it is combined with Bifonazole.Approved, Investigational
Bismuth SubcitrateThe serum concentration of Fluvastatin can be decreased when it is combined with Bismuth Subcitrate.Approved, Investigational
Bismuth subnitrateThe serum concentration of Fluvastatin can be decreased when it is combined with Bismuth subnitrate.Approved, Experimental
BoceprevirThe metabolism of Fluvastatin can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Fluvastatin can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe metabolism of Fluvastatin can be increased when combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Fluvastatin.Approved
Brefeldin AThe risk or severity of rhabdomyolysis can be increased when Brefeldin A is combined with Fluvastatin.Experimental
Brentuximab vedotinThe serum concentration of Fluvastatin can be increased when it is combined with Brentuximab vedotin.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Fluvastatin.Approved, Investigational
BromocriptineThe serum concentration of Fluvastatin can be increased when it is combined with Bromocriptine.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Fluvastatin.Approved
Bryostatin 1The risk or severity of rhabdomyolysis can be increased when Bryostatin 1 is combined with Fluvastatin.Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Fluvastatin.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Fluvastatin can be decreased when combined with Bupropion.Approved
CabergolineThe serum concentration of Fluvastatin can be increased when it is combined with Cabergoline.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Fluvastatin.Approved, Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Fluvastatin.Approved
Calcium CarbonateThe serum concentration of Fluvastatin can be decreased when it is combined with Calcium Carbonate.Approved, Investigational
Calcium silicateThe serum concentration of Fluvastatin can be decreased when it is combined with Calcium silicate.Experimental
CandesartanThe metabolism of Candesartan can be decreased when combined with Fluvastatin.Experimental
Candesartan cilexetilThe metabolism of Candesartan cilexetil can be decreased when combined with Fluvastatin.Approved
CandicidinThe risk or severity of rhabdomyolysis can be increased when Candicidin is combined with Fluvastatin.Withdrawn
CannabidiolThe metabolism of Cannabidiol can be decreased when combined with Fluvastatin.Approved, Investigational
CapecitabineThe metabolism of Fluvastatin can be decreased when combined with Capecitabine.Approved, Investigational
CapsaicinThe serum concentration of Fluvastatin can be increased when it is combined with Capsaicin.Approved
CarbamazepineThe metabolism of Fluvastatin can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Fluvastatin.Approved
CarbomycinThe risk or severity of rhabdomyolysis can be increased when Carbomycin is combined with Fluvastatin.Vet Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Fluvastatin.Approved, Investigational
CaspofunginThe serum concentration of Fluvastatin can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Fluvastatin can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Fluvastatin can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Fluvastatin.Approved, Withdrawn
CethromycinThe risk or severity of rhabdomyolysis can be increased when Cethromycin is combined with Fluvastatin.Investigational
ChloramphenicolThe serum concentration of Fluvastatin can be increased when it is combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe metabolism of Fluvastatin can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorpromazineThe metabolism of Fluvastatin can be decreased when combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Fluvastatin.Approved, Investigational
ChlorzoxazoneThe serum concentration of Fluvastatin can be increased when it is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Fluvastatin can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineThe serum concentration of Fluvastatin can be decreased when it is combined with Cholestyramine.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Fluvastatin.Approved, Investigational
CimetidineThe serum concentration of Fluvastatin can be increased when it is combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Fluvastatin can be decreased when combined with Cinacalcet.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Fluvastatin.Approved, Investigational
CiprofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofibrate is combined with Fluvastatin.Approved, Investigational
CiprofloxacinThe serum concentration of Fluvastatin can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Fluvastatin.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Fluvastatin can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Fluvastatin can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Fluvastatin can be decreased when combined with Clemastine.Approved, Investigational
ClindamycinThe serum concentration of Fluvastatin can be increased when it is combined with Clindamycin.Approved, Vet Approved
ClobazamThe metabolism of Fluvastatin can be decreased when combined with Clobazam.Approved, Illicit
ClofazimineThe serum concentration of Fluvastatin can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Fluvastatin can be increased when it is combined with Clomifene.Approved, Investigational
ClomipramineThe metabolism of Fluvastatin can be decreased when combined with Clomipramine.Approved, Investigational, Vet Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Fluvastatin.Approved
ClotiazepamThe serum concentration of Fluvastatin can be increased when it is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe metabolism of Fluvastatin can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Fluvastatin can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Fluvastatin can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Fluvastatin can be decreased when combined with Cocaine.Approved, Illicit
ColchicineColchicine may increase the myopathic rhabdomyolysis activities of Fluvastatin.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Fluvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Fluvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Coltuximab ravtansineThe risk or severity of rhabdomyolysis can be increased when Coltuximab ravtansine is combined with Fluvastatin.Investigational
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Fluvastatin.Approved, Investigational
Cortisone acetateThe serum concentration of Fluvastatin can be increased when it is combined with Cortisone acetate.Approved, Investigational
CrisaboroleThe metabolism of Fluvastatin can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibThe metabolism of Fluvastatin can be decreased when combined with Crizotinib.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Fluvastatin.Approved, Investigational
CyclosporineThe serum concentration of Fluvastatin can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Fluvastatin can be increased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Fluvastatin can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaclatasvirThe serum concentration of Fluvastatin can be increased when it is combined with Daclatasvir.Approved, Investigational
DalfopristinThe serum concentration of Fluvastatin can be increased when it is combined with Dalfopristin.Approved
DanazolThe risk or severity of myopathy and rhabdomyolysis can be increased when Danazol is combined with Fluvastatin.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Fluvastatin.Approved
DapsoneThe metabolism of Dapsone can be decreased when combined with Fluvastatin.Approved, Investigational
DaptomycinThe risk or severity of adverse effects can be increased when Fluvastatin is combined with Daptomycin.Approved, Investigational
DarifenacinThe metabolism of Fluvastatin can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Fluvastatin can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Fluvastatin can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Fluvastatin can be increased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Fluvastatin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Fluvastatin can be decreased when combined with Delavirdine.Approved
DesipramineThe metabolism of Fluvastatin can be decreased when combined with Desipramine.Approved, Investigational
DexamethasoneThe serum concentration of Fluvastatin can be increased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Fluvastatin.Approved
DextropropoxypheneThe serum concentration of Fluvastatin can be increased when it is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Fluvastatin.Approved, Illicit, Investigational, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Fluvastatin.Approved, Vet Approved
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Fluvastatin.Approved
DiethylstilbestrolThe serum concentration of Fluvastatin can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Fluvastatin.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Fluvastatin.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Fluvastatin.Experimental
DihydroergotamineThe metabolism of Fluvastatin can be decreased when combined with Dihydroergotamine.Approved, Investigational
DiltiazemThe metabolism of Fluvastatin can be decreased when combined with Diltiazem.Approved, Investigational
Dimethyl sulfoxideThe serum concentration of Fluvastatin can be increased when it is combined with Dimethyl sulfoxide.Approved, Vet Approved
DiphenhydramineThe metabolism of Fluvastatin can be decreased when combined with Diphenhydramine.Approved, Investigational
DirithromycinThe risk or severity of rhabdomyolysis can be increased when Dirithromycin is combined with Fluvastatin.Approved, Investigational
DocetaxelThe serum concentration of Fluvastatin can be increased when it is combined with Docetaxel.Approved, Investigational
DoconexentThe metabolism of Doconexent can be decreased when combined with Fluvastatin.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Fluvastatin.Approved, Investigational
DonepezilThe metabolism of Donepezil can be decreased when combined with Fluvastatin.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Fluvastatin.Approved
DoramectinThe risk or severity of rhabdomyolysis can be increased when Doramectin is combined with Fluvastatin.Vet Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Fluvastatin.Approved
DosulepinThe metabolism of Fluvastatin can be decreased when combined with Dosulepin.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Fluvastatin.Approved, Investigational
DoxorubicinThe serum concentration of Fluvastatin can be increased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Fluvastatin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Fluvastatin.Approved, Illicit
DronedaroneThe serum concentration of Fluvastatin can be increased when it is combined with Dronedarone.Approved
DuloxetineThe metabolism of Fluvastatin can be decreased when combined with Duloxetine.Approved
EconazoleThe serum concentration of Fluvastatin can be increased when it is combined with Econazole.Approved
EfavirenzThe serum concentration of Fluvastatin can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Fluvastatin can be increased when it is combined with Elbasvir.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Fluvastatin.Approved, Investigational
EliglustatThe metabolism of Fluvastatin can be decreased when combined with Eliglustat.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Fluvastatin.Approved, Investigational
EnzalutamideThe serum concentration of Fluvastatin can be decreased when it is combined with Enzalutamide.Approved
EpinephrineThe serum concentration of Fluvastatin can be increased when it is combined with Epinephrine.Approved, Vet Approved
EpofolateThe risk or severity of rhabdomyolysis can be increased when Epofolate is combined with Fluvastatin.Investigational
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Fluvastatin.Approved
Epothilone DThe risk or severity of rhabdomyolysis can be increased when Epothilone D is combined with Fluvastatin.Experimental, Investigational
EprinomectinThe risk or severity of rhabdomyolysis can be increased when Eprinomectin is combined with Fluvastatin.Vet Approved
Ergoloid mesylateThe serum concentration of Fluvastatin can be increased when it is combined with Ergoloid mesylate.Approved
ErgonovineThe serum concentration of Fluvastatin can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Fluvastatin can be increased when it is combined with Ergotamine.Approved
ErlotinibThe risk or severity of adverse effects can be increased when Erlotinib is combined with Fluvastatin.Approved, Investigational
ErythromycinThe serum concentration of Fluvastatin can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EstradiolThe metabolism of Estradiol can be decreased when combined with Fluvastatin.Approved, Investigational, Vet Approved
Estradiol acetateThe metabolism of Estradiol acetate can be decreased when combined with Fluvastatin.Approved, Investigational, Vet Approved
Estradiol benzoateThe metabolism of Estradiol benzoate can be decreased when combined with Fluvastatin.Approved, Investigational, Vet Approved
Estradiol cypionateThe metabolism of Estradiol cypionate can be decreased when combined with Fluvastatin.Approved, Investigational, Vet Approved
Estradiol dienanthateThe metabolism of Estradiol dienanthate can be decreased when combined with Fluvastatin.Approved, Investigational, Vet Approved
Estradiol valerateThe metabolism of Estradiol valerate can be decreased when combined with Fluvastatin.Approved, Investigational, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Fluvastatin.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Fluvastatin.Approved, Investigational
EthanolThe serum concentration of Fluvastatin can be increased when it is combined with Ethanol.Approved
EtodolacThe metabolism of Etodolac can be decreased when combined with Fluvastatin.Approved, Investigational, Vet Approved
EtoposideThe serum concentration of Fluvastatin can be increased when it is combined with Etoposide.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Fluvastatin.Approved, Investigational
EtravirineThe serum concentration of Fluvastatin can be increased when it is combined with Etravirine.Approved
EverolimusThe risk or severity of rhabdomyolysis can be increased when Everolimus is combined with Fluvastatin.Approved
EzetimibeThe serum concentration of Fluvastatin can be increased when it is combined with Ezetimibe.Approved
FelodipineThe metabolism of Fluvastatin can be decreased when combined with Felodipine.Approved, Investigational
FenofibrateThe risk or severity of myopathy and rhabdomyolysis can be increased when Fenofibrate is combined with Fluvastatin.Approved
FentanylThe serum concentration of Fluvastatin can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fluvastatin.Approved
FloxuridineThe metabolism of Fluvastatin can be decreased when combined with Floxuridine.Approved
FluconazoleThe serum concentration of Fluvastatin can be increased when it is combined with Fluconazole.Approved, Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Fluvastatin.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Fluvastatin.Approved, Illicit
FluorouracilThe metabolism of Fluvastatin can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Fluvastatin can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Fluvastatin.Approved, Investigational
FlurithromycinThe risk or severity of rhabdomyolysis can be increased when Flurithromycin is combined with Fluvastatin.Experimental
Fluticasone propionateThe serum concentration of Fluvastatin can be increased when it is combined with Fluticasone propionate.Approved
FluvoxamineThe metabolism of Fluvastatin can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Fluvastatin.Approved, Investigational
FosamprenavirThe metabolism of Fluvastatin can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Fluvastatin can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Fluvastatin can be decreased when it is combined with Fosphenytoin.Approved, Investigational
Fusidic AcidThe serum concentration of Fluvastatin can be increased when it is combined with Fusidic Acid.Approved, Investigational
GavestinelThe metabolism of Gavestinel can be decreased when combined with Fluvastatin.Investigational
GemfibrozilThe risk or severity of rhabdomyolysis, myoglobinuria, and elevated creatine kinase (CPK) can be increased when Gemfibrozil is combined with Fluvastatin.Approved
GliclazideThe metabolism of Gliclazide can be decreased when combined with Fluvastatin.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Fluvastatin.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Fluvastatin.Approved, Investigational
GlyburideThe metabolism of Glyburide can be decreased when combined with Fluvastatin.Approved
Glycerol PhenylbutyrateThe serum concentration of Fluvastatin can be increased when it is combined with Glycerol Phenylbutyrate.Approved
GPI-1485The risk or severity of rhabdomyolysis can be increased when GPI-1485 is combined with Fluvastatin.Investigational
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Fluvastatin.Approved, Investigational
HaloperidolThe metabolism of Fluvastatin can be decreased when combined with Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Fluvastatin.Approved, Vet Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Fluvastatin.Approved
HistamineThe metabolism of Histamine can be decreased when combined with Fluvastatin.Approved, Investigational
HydralazineThe serum concentration of Fluvastatin can be increased when it is combined with Hydralazine.Approved
HydrocortisoneThe serum concentration of Fluvastatin can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Fluvastatin.Approved, Illicit
HydrotalciteThe serum concentration of Fluvastatin can be decreased when it is combined with Hydrotalcite.Approved, Experimental, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Fluvastatin.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Fluvastatin.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Fluvastatin.Approved
IdelalisibThe metabolism of Fluvastatin can be decreased when combined with Idelalisib.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Fluvastatin.Approved
IloperidoneThe serum concentration of Fluvastatin can be increased when it is combined with Iloperidone.Approved
ImatinibThe metabolism of Fluvastatin can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Fluvastatin can be decreased when combined with Imipramine.Approved
IndinavirThe metabolism of Fluvastatin can be decreased when combined with Indinavir.Approved
IndisulamThe metabolism of Indisulam can be decreased when combined with Fluvastatin.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Fluvastatin.Approved, Investigational
IrbesartanThe metabolism of Fluvastatin can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Fluvastatin can be increased when it is combined with Irinotecan.Approved, Investigational
IsavuconazoniumThe metabolism of Fluvastatin can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Fluvastatin can be decreased when combined with Isoniazid.Approved, Investigational
IsradipineThe metabolism of Fluvastatin can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe serum concentration of Fluvastatin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Fluvastatin can be increased when it is combined with Ivacaftor.Approved
IvermectinThe risk or severity of rhabdomyolysis can be increased when Ivermectin is combined with Fluvastatin.Approved, Investigational, Vet Approved
IxabepiloneThe risk or severity of rhabdomyolysis can be increased when Ixabepilone is combined with Fluvastatin.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Fluvastatin.Approved, Investigational
JosamycinThe risk or severity of rhabdomyolysis can be increased when Josamycin is combined with Fluvastatin.Approved, Investigational
KetamineThe metabolism of Ketamine can be decreased when combined with Fluvastatin.Approved, Vet Approved
KetazolamThe serum concentration of Fluvastatin can be increased when it is combined with Ketazolam.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Fluvastatin.Approved, Investigational
KetoconazoleThe serum concentration of Fluvastatin can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Fluvastatin.Approved, Vet Approved
KitasamycinThe risk or severity of rhabdomyolysis can be increased when Kitasamycin is combined with Fluvastatin.Experimental
KOS-1584The risk or severity of rhabdomyolysis can be increased when KOS-1584 is combined with Fluvastatin.Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Fluvastatin.Approved, Investigational
Lanthanum carbonateThe serum concentration of Fluvastatin can be decreased when it is combined with Lanthanum carbonate.Approved
LapatinibThe metabolism of Fluvastatin can be decreased when combined with Lapatinib.Approved, Investigational
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Fluvastatin.Approved, Investigational
LercanidipineThe serum concentration of Fluvastatin can be increased when it is combined with Lercanidipine.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Fluvastatin.Approved, Investigational
LevofloxacinThe serum concentration of Fluvastatin can be increased when it is combined with Levofloxacin.Approved, Investigational
LevosalbutamolThe serum concentration of Fluvastatin can be increased when it is combined with Levosalbutamol.Approved, Investigational
LicofeloneThe metabolism of Licofelone can be decreased when combined with Fluvastatin.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Fluvastatin.Approved, Vet Approved
LinagliptinThe serum concentration of Fluvastatin can be increased when it is combined with Linagliptin.Approved
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Fluvastatin.Approved, Investigational
LobeglitazoneThe metabolism of Fluvastatin can be decreased when combined with Lobeglitazone.Approved, Investigational
LomitapideThe serum concentration of Fluvastatin can be increased when it is combined with Lomitapide.Approved, Investigational
LomustineThe serum concentration of Fluvastatin can be increased when it is combined with Lomustine.Approved, Investigational
LopinavirThe metabolism of Fluvastatin can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Fluvastatin.Approved, Investigational
LorcaserinThe metabolism of Fluvastatin can be decreased when combined with Lorcaserin.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Fluvastatin.Approved, Investigational
LorpiprazoleThe serum concentration of Fluvastatin can be increased when it is combined with Lorpiprazole.Approved
Lorvotuzumab mertansineThe risk or severity of rhabdomyolysis can be increased when Lorvotuzumab mertansine is combined with Fluvastatin.Investigational
LosartanThe metabolism of Fluvastatin can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Fluvastatin can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Fluvastatin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Fluvastatin can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Fluvastatin can be decreased when combined with Lumefantrine.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Fluvastatin.Approved, Investigational
LurasidoneThe serum concentration of Fluvastatin can be increased when it is combined with Lurasidone.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Fluvastatin.Illicit, Investigational, Withdrawn
MagaldrateThe serum concentration of Fluvastatin can be decreased when it is combined with Magaldrate.Approved, Withdrawn
Magnesium hydroxideThe serum concentration of Fluvastatin can be decreased when it is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe serum concentration of Fluvastatin can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Fluvastatin can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium silicateThe serum concentration of Fluvastatin can be decreased when it is combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe serum concentration of Fluvastatin can be decreased when it is combined with Magnesium Trisilicate.Approved
ManidipineThe metabolism of Fluvastatin can be decreased when combined with Manidipine.Approved, Investigational
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Fluvastatin.Approved
MefloquineThe serum concentration of Fluvastatin can be increased when it is combined with Mefloquine.Approved, Investigational
MelatoninThe metabolism of Melatonin can be decreased when combined with Fluvastatin.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Fluvastatin.Approved, Vet Approved
MepartricinThe risk or severity of rhabdomyolysis can be increased when Mepartricin is combined with Fluvastatin.Experimental
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Fluvastatin.Investigational, Withdrawn
MequitazineThe serum concentration of Fluvastatin can be increased when it is combined with Mequitazine.Approved
MestranolThe metabolism of Mestranol can be decreased when combined with Fluvastatin.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Fluvastatin.Experimental
MethadoneThe metabolism of Fluvastatin can be decreased when combined with Methadone.Approved
MethazolamideThe serum concentration of Fluvastatin can be increased when it is combined with Methazolamide.Approved
MethimazoleThe serum concentration of Fluvastatin can be increased when it is combined with Methimazole.Approved
MethotrimeprazineThe metabolism of Fluvastatin can be decreased when combined with Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Fluvastatin.Approved, Investigational, Vet Approved
MethylergometrineThe serum concentration of Fluvastatin can be increased when it is combined with Methylergometrine.Approved
MethylprednisoloneThe serum concentration of Fluvastatin can be increased when it is combined with Methylprednisolone.Approved, Vet Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Fluvastatin.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Fluvastatin.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Fluvastatin.Approved
MetyraponeThe serum concentration of Fluvastatin can be increased when it is combined with Metyrapone.Approved, Investigational
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Fluvastatin.Experimental
MibefradilThe serum concentration of Fluvastatin can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Fluvastatin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Fluvastatin can be increased when it is combined with Midazolam.Approved, Illicit
MidecamycinThe risk or severity of rhabdomyolysis can be increased when Midecamycin is combined with Fluvastatin.Experimental
MidostaurinThe metabolism of Fluvastatin can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Fluvastatin can be increased when it is combined with Mifepristone.Approved, Investigational
MiocamycinThe risk or severity of rhabdomyolysis can be increased when Miocamycin is combined with Fluvastatin.Experimental
MirabegronThe metabolism of Fluvastatin can be decreased when combined with Mirabegron.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Fluvastatin.Approved
Mirvetuximab SoravtansineThe risk or severity of rhabdomyolysis can be increased when Mirvetuximab Soravtansine is combined with Fluvastatin.Investigational
MitemcinalThe risk or severity of rhabdomyolysis can be increased when Mitemcinal is combined with Fluvastatin.Investigational
MitotaneThe serum concentration of Fluvastatin can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Fluvastatin can be increased when it is combined with Mitoxantrone.Approved, Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Fluvastatin.Approved, Investigational
ModafinilThe serum concentration of Fluvastatin can be increased when it is combined with Modafinil.Approved, Investigational
MontelukastThe metabolism of Montelukast can be decreased when combined with Fluvastatin.Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Fluvastatin.Approved, Vet Approved
NatamycinThe risk or severity of rhabdomyolysis can be increased when Natamycin is combined with Fluvastatin.Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Fluvastatin.Approved, Investigational
NefazodoneThe metabolism of Fluvastatin can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Fluvastatin can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Fluvastatin can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Fluvastatin can be increased when combined with Nevirapine.Approved
NiacinThe risk or severity of rhabdomyolysis can be increased when Niacin is combined with Fluvastatin.Approved, Investigational, Nutraceutical
NicardipineThe metabolism of Fluvastatin can be decreased when combined with Nicardipine.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Fluvastatin.Approved, Investigational
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Fluvastatin.Approved, Investigational, Vet Approved
NicotinamideThe serum concentration of Fluvastatin can be increased when it is combined with Nicotinamide.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Fluvastatin.Approved
NifedipineThe serum concentration of Fluvastatin can be increased when it is combined with Nifedipine.Approved
NilotinibThe metabolism of Fluvastatin can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe serum concentration of Fluvastatin can be increased when it is combined with Nilvadipine.Approved, Investigational
NisoldipineThe serum concentration of Fluvastatin can be increased when it is combined with Nisoldipine.Approved
NitrendipineThe serum concentration of Fluvastatin can be increased when it is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe serum concentration of Fluvastatin can be increased when it is combined with Nitric Oxide.Approved
NorfloxacinThe serum concentration of Fluvastatin can be increased when it is combined with Norfloxacin.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Fluvastatin.Approved
NoscapineThe serum concentration of Fluvastatin can be increased when it is combined with Noscapine.Investigational
NystatinThe risk or severity of rhabdomyolysis can be increased when Nystatin is combined with Fluvastatin.Approved, Vet Approved
OlanzapineThe serum concentration of Fluvastatin can be increased when it is combined with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Fluvastatin can be decreased when combined with Olaparib.Approved
OleandomycinThe risk or severity of rhabdomyolysis can be increased when Oleandomycin is combined with Fluvastatin.Vet Approved
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Fluvastatin.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Fluvastatin.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Fluvastatin.Approved
OsimertinibThe serum concentration of Fluvastatin can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Fluvastatin.Approved, Investigational
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Fluvastatin.Approved
OxybutyninThe serum concentration of Fluvastatin can be increased when it is combined with Oxybutynin.Approved, Investigational
OxymetholoneThe serum concentration of Fluvastatin can be increased when it is combined with Oxymetholone.Approved, Illicit
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Fluvastatin.Approved, Vet Approved
PalbociclibThe serum concentration of Fluvastatin can be increased when it is combined with Palbociclib.Approved, Investigational
PanobinostatThe serum concentration of Fluvastatin can be increased when it is combined with Panobinostat.Approved, Investigational
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Fluvastatin.Approved
ParamethasoneThe serum concentration of Fluvastatin can be increased when it is combined with Paramethasone.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Fluvastatin.Approved
ParoxetineThe metabolism of Fluvastatin can be decreased when combined with Paroxetine.Approved, Investigational
PatupiloneThe risk or severity of rhabdomyolysis can be increased when Patupilone is combined with Fluvastatin.Experimental, Investigational
PazopanibFluvastatin may increase the hepatotoxic activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Fluvastatin can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentobarbitalThe metabolism of Fluvastatin can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PergolideThe serum concentration of Fluvastatin can be increased when it is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Fluvastatin.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Fluvastatin.Withdrawn
PhenelzineThe serum concentration of Fluvastatin can be increased when it is combined with Phenelzine.Approved
PhenobarbitalThe metabolism of Fluvastatin can be increased when combined with Phenobarbital.Approved, Investigational
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Fluvastatin.Approved, Investigational
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Fluvastatin.Approved, Vet Approved
PhenytoinThe serum concentration of Fluvastatin can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe serum concentration of Fluvastatin can be increased when it is combined with Pilocarpine.Approved, Investigational
PimecrolimusThe risk or severity of rhabdomyolysis can be increased when Pimecrolimus is combined with Fluvastatin.Approved, Investigational
PimozideThe serum concentration of Fluvastatin can be increased when it is combined with Pimozide.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Fluvastatin.Approved, Investigational
PiperaquineThe metabolism of Piperaquine can be decreased when combined with Fluvastatin.Approved, Investigational
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Fluvastatin.Approved, Investigational
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Fluvastatin.Approved
PosaconazoleThe metabolism of Fluvastatin can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Fluvastatin.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Fluvastatin.Approved
PrednisoloneThe serum concentration of Fluvastatin can be increased when it is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe serum concentration of Fluvastatin can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimaquineThe serum concentration of Fluvastatin can be increased when it is combined with Primaquine.Approved
PrimidoneThe metabolism of Fluvastatin can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Fluvastatin.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Fluvastatin.Approved
PromazineThe metabolism of Fluvastatin can be decreased when combined with Promazine.Approved, Vet Approved
PropofolThe metabolism of Propofol can be decreased when combined with Fluvastatin.Approved, Investigational, Vet Approved
PyrimethamineThe metabolism of Fluvastatin can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Fluvastatin.Approved, Illicit
QuinidineThe metabolism of Fluvastatin can be decreased when combined with Quinidine.Approved, Investigational
QuinineThe metabolism of Fluvastatin can be decreased when combined with Quinine.Approved
QuinupristinThe serum concentration of Fluvastatin can be increased when it is combined with Quinupristin.Approved
RabeprazoleThe metabolism of Fluvastatin can be decreased when combined with Rabeprazole.Approved, Investigational
RaloxifeneThe serum concentration of Fluvastatin can be increased when it is combined with Raloxifene.Approved, Investigational
RaltegravirRaltegravir may increase the myopathic rhabdomyolysis activities of Fluvastatin.Approved
RanitidineThe serum concentration of Fluvastatin can be increased when it is combined with Ranitidine.Approved
RanolazineThe metabolism of Fluvastatin can be decreased when combined with Ranolazine.Approved, Investigational
RegorafenibThe serum concentration of Fluvastatin can be increased when it is combined with Regorafenib.Approved
RepaglinideThe serum concentration of Fluvastatin can be increased when it is combined with Repaglinide.Approved, Investigational
ResveratrolThe serum concentration of Fluvastatin can be increased when it is combined with Resveratrol.Approved, Experimental, Investigational
RidaforolimusThe risk or severity of rhabdomyolysis can be increased when Ridaforolimus is combined with Fluvastatin.Investigational
RifabutinThe metabolism of Fluvastatin can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Fluvastatin can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Fluvastatin can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Fluvastatin can be decreased when it is combined with Rifaximin.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Fluvastatin.Approved
RisperidoneThe serum concentration of Fluvastatin can be increased when it is combined with Risperidone.Approved, Investigational
RitonavirThe metabolism of Fluvastatin can be decreased when combined with Ritonavir.Approved, Investigational
RivastigmineThe serum concentration of Fluvastatin can be increased when it is combined with Rivastigmine.Approved, Investigational
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Fluvastatin.Approved, Investigational, Withdrawn
RokitamycinThe risk or severity of rhabdomyolysis can be increased when Rokitamycin is combined with Fluvastatin.Experimental
RolapitantThe metabolism of Fluvastatin can be decreased when combined with Rolapitant.Approved, Investigational
RolitetracyclineThe serum concentration of Fluvastatin can be increased when it is combined with Rolitetracycline.Approved
RopiniroleThe metabolism of Fluvastatin can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Fluvastatin.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Fluvastatin.Approved
RoxithromycinThe risk or severity of rhabdomyolysis can be increased when Roxithromycin is combined with Fluvastatin.Approved, Investigational, Withdrawn
RucaparibThe metabolism of Fluvastatin can be decreased when combined with Rucaparib.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Fluvastatin.Approved
RutinThe serum concentration of Fluvastatin can be increased when it is combined with Rutin.Experimental, Investigational
SagopiloneThe risk or severity of rhabdomyolysis can be increased when Sagopilone is combined with Fluvastatin.Investigational
SalbutamolThe serum concentration of Fluvastatin can be increased when it is combined with Salbutamol.Approved, Vet Approved
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Fluvastatin.Approved, Investigational, Vet Approved
SaquinavirThe metabolism of Fluvastatin can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Fluvastatin can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Fluvastatin.Approved
SecobarbitalThe metabolism of Fluvastatin can be increased when combined with Secobarbital.Approved, Vet Approved
SelamectinThe risk or severity of rhabdomyolysis can be increased when Selamectin is combined with Fluvastatin.Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Fluvastatin.Approved, Investigational, Vet Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Fluvastatin.Approved
SertralineThe metabolism of Fluvastatin can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Fluvastatin can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Fluvastatin can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Fluvastatin can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Simvastatin.Approved
SirolimusThe risk or severity of rhabdomyolysis can be increased when Sirolimus is combined with Fluvastatin.Approved, Investigational
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Fluvastatin.Approved, Investigational, Withdrawn
Sodium bicarbonateThe serum concentration of Fluvastatin can be decreased when it is combined with Sodium bicarbonate.Approved
SorafenibThe metabolism of Fluvastatin can be decreased when combined with Sorafenib.Approved, Investigational
SpiramycinThe risk or severity of rhabdomyolysis can be increased when Spiramycin is combined with Fluvastatin.Approved
St. John's WortThe metabolism of Fluvastatin can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Fluvastatin can be increased when it is combined with Stiripentol.Approved
SulfadiazineThe metabolism of Fluvastatin can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Fluvastatin can be decreased when combined with Sulfamethoxazole.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Fluvastatin.Approved
SulfanilamideThe serum concentration of Fluvastatin can be increased when it is combined with Sulfanilamide.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Fluvastatin.Approved
SulfisoxazoleThe metabolism of Fluvastatin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SuprofenThe metabolism of Suprofen can be decreased when combined with Fluvastatin.Approved, Withdrawn
TacrolimusThe risk or severity of rhabdomyolysis can be increased when Tacrolimus is combined with Fluvastatin.Approved, Investigational
TadalafilThe serum concentration of Fluvastatin can be increased when it is combined with Tadalafil.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Fluvastatin.Approved
TapentadolThe metabolism of Tapentadol can be decreased when combined with Fluvastatin.Approved
TelaprevirThe metabolism of Fluvastatin can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe risk or severity of rhabdomyolysis can be increased when Telithromycin is combined with Fluvastatin.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Fluvastatin.Approved, Investigational
TemsirolimusThe risk or severity of rhabdomyolysis can be increased when Temsirolimus is combined with Fluvastatin.Approved
TeniposideThe serum concentration of Fluvastatin can be increased when it is combined with Teniposide.Approved
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Fluvastatin.Approved
TerbinafineThe metabolism of Fluvastatin can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Fluvastatin.Approved, Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Fluvastatin.Experimental
TeriflunomideThe metabolism of Fluvastatin can be decreased when combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Fluvastatin can be increased when it is combined with Tesmilifene.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Fluvastatin.Approved, Investigational
Testosterone cypionateThe metabolism of Testosterone cypionate can be decreased when combined with Fluvastatin.Approved
Testosterone enanthateThe metabolism of Testosterone enanthate can be decreased when combined with Fluvastatin.Approved
Testosterone undecanoateThe metabolism of Testosterone undecanoate can be decreased when combined with Fluvastatin.Approved, Investigational
TetracyclineThe serum concentration of Fluvastatin can be increased when it is combined with Tetracycline.Approved, Vet Approved
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Fluvastatin.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Fluvastatin.Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Fluvastatin.Approved, Vet Approved
ThiopentalThe serum concentration of Fluvastatin can be increased when it is combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Fluvastatin.Approved, Withdrawn
TicagrelorThe metabolism of Fluvastatin can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Fluvastatin can be decreased when combined with Ticlopidine.Approved
TildipirosinThe risk or severity of rhabdomyolysis can be increased when Tildipirosin is combined with Fluvastatin.Vet Approved
TilmicosinThe risk or severity of rhabdomyolysis can be increased when Tilmicosin is combined with Fluvastatin.Investigational, Vet Approved
TioconazoleThe serum concentration of Fluvastatin can be increased when it is combined with Tioconazole.Approved
TipranavirThe metabolism of Fluvastatin can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Fluvastatin.Approved, Investigational
TocilizumabThe serum concentration of Fluvastatin can be decreased when it is combined with Tocilizumab.Approved
TofisopamThe serum concentration of Fluvastatin can be increased when it is combined with Tofisopam.Approved
TolbutamideThe metabolism of Fluvastatin can be decreased when combined with Tolbutamide.Approved, Investigational
TolterodineThe metabolism of Tolterodine can be decreased when combined with Fluvastatin.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Fluvastatin.Approved
TopiroxostatThe metabolism of Fluvastatin can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Fluvastatin can be increased when it is combined with Topotecan.Approved, Investigational
TorasemideThe metabolism of Torasemide can be decreased when combined with Fluvastatin.Approved
TrabectedinFluvastatin may increase the myopathic rhabdomyolysis activities of Trabectedin.Approved, Investigational
TramadolThe serum concentration of Fluvastatin can be increased when it is combined with Tramadol.Approved, Investigational
TranylcypromineThe metabolism of Fluvastatin can be decreased when combined with Tranylcypromine.Approved, Investigational
Trastuzumab emtansineThe risk or severity of rhabdomyolysis can be increased when Trastuzumab emtansine is combined with Fluvastatin.Approved, Investigational
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Fluvastatin.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Fluvastatin.Approved, Investigational, Nutraceutical
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Fluvastatin.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Fluvastatin.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Fluvastatin.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Fluvastatin.Investigational, Withdrawn
TroleandomycinThe risk or severity of rhabdomyolysis can be increased when Troleandomycin is combined with Fluvastatin.Approved
TromethamineThe serum concentration of Fluvastatin can be decreased when it is combined with Tromethamine.Approved
TylosinThe risk or severity of rhabdomyolysis can be increased when Tylosin is combined with Fluvastatin.Vet Approved
TylvalosinThe risk or severity of rhabdomyolysis can be increased when Tylvalosin is combined with Fluvastatin.Vet Approved
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Fluvastatin.Approved, Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Fluvastatin.Approved, Investigational
ValsartanThe metabolism of Valsartan can be decreased when combined with Fluvastatin.Approved, Investigational
VemurafenibThe serum concentration of Fluvastatin can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Fluvastatin can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Fluvastatin can be decreased when combined with Verapamil.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Fluvastatin.Investigational
VinblastineThe serum concentration of Fluvastatin can be increased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Fluvastatin can be increased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Fluvastatin can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Fluvastatin.Approved, Investigational
VoriconazoleThe serum concentration of Fluvastatin can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Fluvastatin.Approved, Investigational
WarfarinThe metabolism of Warfarin can be decreased when combined with Fluvastatin.Approved
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Fluvastatin.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Fluvastatin can be decreased when combined with Zafirlukast.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Fluvastatin.Approved, Investigational
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Fluvastatin.Approved, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Fluvastatin.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Fluvastatin.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Fluvastatin can be decreased when combined with Ziprasidone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Fluvastatin.Approved
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Fluvastatin.Approved
ZucapsaicinThe serum concentration of Fluvastatin can be increased when it is combined with Zucapsaicin.Approved, Investigational
Food Interactions
  • May be taken with or without food, but should be taken consistently.
  • When given with an evening meal, Cmax and AUC decreased while Tmax increased 2-fold

References

Synthesis Reference

Gustavo Frenkel, Eyal Gilboa, "Process for the preparation of fluvastatin sodium crystal form XIV." U.S. Patent US20050119342, issued June 02, 2005.

US20050119342
General References
  1. Toda T, Eliasson E, Ask B, Inotsume N, Rane A: Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes. Basic Clin Pharmacol Toxicol. 2009 Nov;105(5):327-32. doi: 10.1111/j.1742-7843.2009.00453.x. Epub 2009 Aug 6. [PubMed:19663817]
External Links
Human Metabolome Database
HMDB0015227
KEGG Drug
D07983
KEGG Compound
C07014
PubChem Compound
1548972
PubChem Substance
46505668
ChemSpider
1265982
ChEBI
5136
ChEMBL
CHEMBL350239
Therapeutic Targets Database
DAP000554
PharmGKB
PA449688
HET
115
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Fluvastatin
ATC Codes
C10AA04 — Fluvastatin
AHFS Codes
  • 24:06.08 — Hmg-coa Reductase Inhibitors
FDA label
Download (84.5 KB)
MSDS
Download (101 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceHealthy Volunteers1
1SuspendedTreatmentGliomas1
2CompletedTreatmentAlport Syndrome1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection1
2CompletedTreatmentProstate Cancer1
2TerminatedPreventionAging / Inflammatory Reaction1
2Unknown StatusBasic ScienceAntiphospholipid Syndrome1
2Unknown StatusTreatmentAortic Valve Stenosis1
2WithdrawnTreatmentHepatitis C Viral Infection / Hepatitis C Virus (HCV)1
2, 3TerminatedPreventionTransplantation, Renal1
3CompletedTreatmentAtherosclerosis / Cardiovascular Disease (CVD)1
3CompletedTreatmentChronic Nephropathy / High Blood Pressure (Hypertension) / Proteinuria1
3CompletedTreatmentDyslipidemias1
3CompletedTreatmentHeterozygous Familial Hypercholesterolemia / Mixed hypercholesterolemia1
3CompletedTreatmentHigh Blood Cholesterol Level1
3CompletedTreatmentHigh Blood Cholesterol Level / Mixed hypercholesterolemia1
3TerminatedTreatmentHigh Blood Cholesterol Level1
4CompletedNot AvailableDrug-Interactions1
4CompletedPreventionGraft Vasculopathy1
4CompletedTreatmentCoronary Heart Disease (CHD) / High Blood Cholesterol Level1
4CompletedTreatmentCoronary Heart Disease (CHD) / Myocardial Infarction (MI)1
4CompletedTreatmentDyslipidemias3
4CompletedTreatmentDyslipidemias / High Blood Pressure (Hypertension)1
4CompletedTreatmentHigh Blood Cholesterol Level1
4CompletedTreatmentHypertension, Dyslypidaemia1
4CompletedTreatmentLipid Metabolism Disorders1
4CompletedTreatmentMetabolic Syndromes2
4CompletedTreatmentChronic, stable Angina pectoris / Non ST Segment Elevation Myocardial Infarction (NSTEMI) / Unstable Angina Pectoris1
4CompletedTreatmentBone destruction1
4RecruitingBasic ScienceAdipose Tissue, Brown / Clinical Trial / Insulin Resistance1
4RecruitingPreventionHigh Blood Pressure (Hypertension) / Strokes / Transient Ischaemic Attack (TIA)1
4RecruitingTreatmentCoronary Artery Disease1
4SuspendedPreventionAortic Valve Stenosis1
4Unknown StatusPreventionHeart Transplantation / High Blood Cholesterol Level1
4Unknown StatusTreatmentAtherosclerosis / Coronary Heart Disease (CHD)1
Not AvailableCompletedNot AvailableCardiovascular Disease (CVD) / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableHigh Blood Cholesterol Level1
Not AvailableCompletedPreventionAtherosclerosis1
Not AvailableCompletedTreatmentHepatitis C Viral Infection1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
Tablet, film coated, extended releaseOral80 mg/1
CapsuleOral20 mg/1
CapsuleOral40 mg/1
CapsuleOral20 mg
CapsuleOral40 mg
Tablet, extended releaseOral80 mg/1
Tablet, extended releaseOral80 mg
Prices
Unit descriptionCostUnit
Lescol XL 80 mg 24 Hour tablet4.25USD tablet
Lescol xl 80 mg tablet4.24USD tablet
Lescol xl 80 mg tablet sa3.66USD tablet
Lescol 20 mg capsule3.38USD capsule
Lescol 40 mg capsule3.37USD capsule
Lescol Xl 80 mg Extended-Release Tablet1.62USD tablet
Lescol 40 mg Capsule1.35USD capsule
Lescol 20 mg Capsule0.96USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5354772No1994-10-112011-10-11Us
CA2346868No2008-09-092019-10-12Canada
CA2085037No2000-11-282012-12-10Canada
US6242003Yes2000-10-132020-10-13Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)194-197 °CHojjati, Mohammad; Journal of Supercritical Fluids 2007, V41(2), P187-194 CAPLUS
water solubility0.46 mg/LNot Available
logP4.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00441 mg/mLALOGPS
logP3.69ALOGPS
logP3.83ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)4.56ChemAxon
pKa (Strongest Basic)-2.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area82.69 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity114.86 m3·mol-1ChemAxon
Polarizability44.31 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9943
Blood Brain Barrier+0.9382
Caco-2 permeable-0.5053
P-glycoprotein substrateNon-substrate0.5176
P-glycoprotein inhibitor INon-inhibitor0.7395
P-glycoprotein inhibitor IINon-inhibitor0.8381
Renal organic cation transporterNon-inhibitor0.8823
CYP450 2C9 substrateNon-substrate0.7305
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.6111
CYP450 1A2 substrateNon-inhibitor0.6003
CYP450 2C9 inhibitorNon-inhibitor0.675
CYP450 2D6 inhibitorNon-inhibitor0.8983
CYP450 2C19 inhibitorNon-inhibitor0.6314
CYP450 3A4 inhibitorNon-inhibitor0.8811
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.809
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.7909
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9472 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9899
hERG inhibition (predictor II)Non-inhibitor0.848
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpyrroles. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrrole ring through a CC or CN bond.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyrroles
Sub Class
Substituted pyrroles
Direct Parent
Phenylpyrroles
Alternative Parents
N-alkylindoles / Indoles / Medium-chain hydroxy acids and derivatives / Medium-chain fatty acids / Beta hydroxy acids and derivatives / Fluorobenzenes / Halogenated fatty acids / Heterocyclic fatty acids / Hydroxy fatty acids / Unsaturated fatty acids
show 12 more
Substituents
3-phenylpyrrole / N-alkylindole / Indole / Indole or derivatives / Medium-chain hydroxy acid / Medium-chain fatty acid / Beta-hydroxy acid / Fluorobenzene / Halobenzene / Halogenated fatty acid
show 28 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
statin (synthetic), (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid (CHEBI:5136)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Nadph binding
Specific Function
Transmembrane glycoprotein that is the rate-limiting enzyme in cholesterol biosynthesis as well as in the biosynthesis of nonsterol isoprenoids that are essential for normal cell function including...
Gene Name
HMGCR
Uniprot ID
P04035
Uniprot Name
3-hydroxy-3-methylglutaryl-coenzyme A reductase
Molecular Weight
97475.155 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Podar K, Tai YT, Hideshima T, Vallet S, Richardson PG, Anderson KC: Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. doi: 10.1517/14728210802676278 . [PubMed:19249983]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Fischer V, Johanson L, Heitz F, Tullman R, Graham E, Baldeck JP, Robinson WT: The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos. 1999 Mar;27(3):410-6. [PubMed:10064574]
  2. Toda T, Eliasson E, Ask B, Inotsume N, Rane A: Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes. Basic Clin Pharmacol Toxicol. 2009 Nov;105(5):327-32. doi: 10.1111/j.1742-7843.2009.00453.x. Epub 2009 Aug 6. [PubMed:19663817]
  3. Scripture CD, Pieper JA: Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet. 2001;40(4):263-81. [PubMed:11368292]
  4. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Kivisto KT, Niemi M, Schaeffeler E, Pitkala K, Tilvis R, Fromm MF, Schwab M, Eichelbaum M, Strandberg T: Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics. 2004 Aug;14(8):523-5. [PubMed:15284534]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Fischer V, Johanson L, Heitz F, Tullman R, Graham E, Baldeck JP, Robinson WT: The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos. 1999 Mar;27(3):410-6. [PubMed:10064574]
  2. Toda T, Eliasson E, Ask B, Inotsume N, Rane A: Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes. Basic Clin Pharmacol Toxicol. 2009 Nov;105(5):327-32. doi: 10.1111/j.1742-7843.2009.00453.x. Epub 2009 Aug 6. [PubMed:19663817]
  3. Scripture CD, Pieper JA: Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet. 2001;40(4):263-81. [PubMed:11368292]
  4. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Fischer V, Johanson L, Heitz F, Tullman R, Graham E, Baldeck JP, Robinson WT: The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos. 1999 Mar;27(3):410-6. [PubMed:10064574]
  2. Toda T, Eliasson E, Ask B, Inotsume N, Rane A: Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes. Basic Clin Pharmacol Toxicol. 2009 Nov;105(5):327-32. doi: 10.1111/j.1742-7843.2009.00453.x. Epub 2009 Aug 6. [PubMed:19663817]
  3. Scripture CD, Pieper JA: Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet. 2001;40(4):263-81. [PubMed:11368292]
  4. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH: Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. [PubMed:11523064]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH: Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. [PubMed:11523064]
  2. Scripture CD, Pieper JA: Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet. 2001;40(4):263-81. [PubMed:11368292]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name
UGT1A3
Uniprot ID
P35503
Uniprot Name
UDP-glucuronosyltransferase 1-3
Molecular Weight
60337.835 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Kopplow K, Letschert K, Konig J, Walter B, Keppler D: Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol. 2005 Oct;68(4):1031-8. Epub 2005 Jul 26. [PubMed:16046661]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
References
  1. Kopplow K, Letschert K, Konig J, Walter B, Keppler D: Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol. 2005 Oct;68(4):1031-8. Epub 2005 Jul 26. [PubMed:16046661]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name
SLCO2B1
Uniprot ID
O94956
Uniprot Name
Solute carrier organic anion transporter family member 2B1
Molecular Weight
76709.98 Da
References
  1. Kopplow K, Letschert K, Konig J, Walter B, Keppler D: Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol. 2005 Oct;68(4):1031-8. Epub 2005 Jul 26. [PubMed:16046661]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Ekins S, Johnston JS, Bahadduri P, D'Souza VM, Ray A, Chang C, Swaan PW: In vitro and pharmacophore-based discovery of novel hPEPT1 inhibitors. Pharm Res. 2005 Apr;22(4):512-7. Epub 2005 Apr 7. [PubMed:15846457]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Ellis LC, Hawksworth GM, Weaver RJ: ATP-dependent transport of statins by human and rat MRP2/Mrp2. Toxicol Appl Pharmacol. 2013 Jun 1;269(2):187-94. doi: 10.1016/j.taap.2013.03.019. Epub 2013 Apr 2. [PubMed:23562342]

Drug created on June 13, 2005 07:24 / Updated on February 21, 2018 17:18